Topics:

Medco Research, Inc. and Repligen Corporation Have Agreed to Merge

Medco Research, Inc. and Repligen Corporation Have Agreed to Merge

CAMBRIDGE, Mass--Repligen Corporation and Medco Research, Inc. (Research Triangle Park, NC) have agreed to merge their two companies. The resulting company's product portfolio will serve three primary markets: cardiovascular disease, oncology, and immunology.

Medco's products include ATP, an adenosine product under investigation as an antitumor agent and to prevent the weight loss and wasting associated with chemotherapy and radiation. Among Repligen's cancer drugs under development is recombinant platelet factor 4 (rPF4), which has shown potential as an antiangiogenesis agent.

 
Loading comments...
Please Wait 20 seconds or click here to close